Epidemiological features of Adamantiades-Behcet's disease in Germany and in Europe.
10.3349/ymj.1997.38.6.411
- Author:
Christos C ZOUBOULIS
1
;
Ina KOTTER
;
Djalil DJAWARI
;
Wilhelm KIRCH
;
Peter K KOHL
;
Falk R OCHSENDORF
;
Wolfgang KEITEL
;
Rudolf STADLER
;
Uwe WOLLINA
;
Ehrhardt PROKSCH
;
Rolf SOHNCHEN
;
Helmut WEBER
;
Harald P GOLLNICK
;
Erhard HOLZLE
;
Klaus FRITZ
;
Thomas LICHT
;
Constantin E ORFANOS
Author Information
1. German Registry of Adamantiades-Behcet's Disease, Department of Dermatology, University Medical Center Benjamin Franklin, Free University of Berlin, Germany. zoubbere@zedat.fu-berlin.de
- Publication Type:Original Article
- Keywords:
Adamantiades-Behcet's disease;
Behcet's disease;
epidemiology;
clinical picture;
prognosis;
Germany;
Europe
- MeSH:
Adolescence;
Adult;
Aged;
Behcet's Syndrome/epidemiology*;
Behcet's Syndrome/complications;
Child;
Child, Preschool;
Europe/epidemiology;
Female;
Germany/epidemiology;
Human;
Male;
Middle Age;
Prognosis
- From:Yonsei Medical Journal
1997;38(6):411-422
- CountryRepublic of Korea
- Language:English
-
Abstract:
The German Registry of Adamantiades-Behcet's disease was founded in 1990 in Berlin and it provides current data on the epidemiology, the clinical manifestations and the course of the disease in Germany on a continuous basis. A total of 218 patients, including 89 German and 100 Turkish patients, had been reported to the German Registry until October 1997. One hundred and ninety-six patients fulfilled the criteria of the Behcet's disease classification tree. The prevalence of the disease evaluated in Berlin-West was 1.68/100,000 in 1989 and had risen to 2.26/100,000 by 1994. The median age of onset was 25 years (range 5 to 66 years; German-Turks, ns). Juvenile disease was recorded in 6.9% of patients. The complete clinical picture according to the criteria of the International Study Group of Behcet's Disease developed in 15.5 months. The interval between onset of the disease and diagnosis was 35 months, which was significantly longer than the duration of the development of the complete clinical picture (p < 0.0001). The disease was diagnosed later in German (48.5 months) than in Turkish patients (25.5 months, p = 0.003). While German patients presented an equal male-to-female ratio, a male predominance was shown in Turkish patients (M:F 2.1:1, p = 0.022). Familial occurrence was detected in 2.0% of German and 15.9% of Turkish patients (p = 0.013). The frequencies of major clinical manifestations were: oral ulcers 99%, skin lesions 76%, genital ulcers 75%, ocular manifestations 59%, arthritis 59%, and positive pathergy test 52%. Clinical differences between German and Turkish patients were only found in the frequency of ocular lesions (48% vs. 66%, p = 0.025). Oral ulcers were with 72% the most common onset symptom of the disease followed by erythema nodosum (9%), uveitis (7%), arthritis (7%), genital ulcers (3%), superficial thrombophlebitis (2%) and papules/sterile pustules (2%). Uveitis and erythema nodosum as onset symptoms shortened the median interval to diagnosis to 1.5 and 15 months, respectively, while arthritis delayed diagnosis (43.5 months; p = 0.029). A severe course developed in 25% of the patients; irreversible retinal vasculitis to blindness in 15%, sterile meningoencephalitis in 8%, severe arthritis in 5%, hemoptysis in 2%, lethal outcome in 2% and bowel perforation in 1%. The relative risk of HLA-B5 positive German natives developing the disease. HLA-B5 was confirmed as a marker of severe prognosis. Cardiolipin autoantibodies were associated with cutaneous vasculitis and superficial thrombophlebitis was correlated with systemic vessel involvement.
